Damora Therapeutics (DMRA) Total Current Liabilities (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Total Current Liabilities came in at $23.8 million in Q1 2026, up 1388.25% YoY from $1.6 million in Q1 2025, and up 18.67% on a QoQ basis from $20.1 million in Q4 2025.
Damora Therapeutics (DMRA) Total Current Liabilities (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Total Current Liabilities data on file, last reported at $23.8 million in Q1 2026.
- Quarterly Total Current Liabilities rose 1388.25% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 1388.25% YoY) and the FY2025 annual result came in at $20.1 million, up 1572.17% from the prior year.
- Total Current Liabilities improved to $23.8 million in Q1 2026, from $20.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $23.8 million in Q1 2026 to a low of $1.2 million in Q4 2024.
- A 5-year average of $8.5 million and a median of $7.2 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities plunged 80.95% — and 2025, when it jumped 1572.17%.
- Tracing DMRA's Total Current Liabilities over 5 years: stood at $11.1 million in 2022, then tumbled by 47.48% to $5.8 million in 2023, then tumbled by 79.42% to $1.2 million in 2024, then jumped by 1572.17% to $20.1 million in 2025, then increased by 18.67% to $23.8 million in 2026.
- The last three Total Current Liabilities figures came in at $23.8 million (Q1 2026), $20.1 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 27.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.60 Mn |
| Mar 31, 2026 | 23.81 Mn |
| Dec 31, 2025 | 20.07 Mn |
| Sep 30, 2025 | 2.62 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 5.83 Mn |
| Sep 30, 2023 | 12.60 Mn |
| Jun 30, 2023 | 14.90 Mn |
| Mar 31, 2023 | 14.06 Mn |
| Dec 31, 2022 | 11.10 Mn |
| Sep 30, 2022 | 8.90 Mn |
| Jun 30, 2022 | 7.50 Mn |
| Mar 31, 2022 | 7.20 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | 5.74 Mn |